外伤性增生性玻璃体视网膜病变防治的研究进展  

Progress in prevention and treatment of traumatic proliferative vitreoretinopathy

作　　者：张琼[1,2] 陈松[1] 

机构地区：[1]天津医科大学眼科临床学院天津市眼科医院天津市眼科学与视觉科学重点实验室天津市眼科研究所,300020 [2]四军医大学唐都医院

出　　处：《国际眼科纵览》2015年第1期60-64,共5页International Review of Ophthalmology

摘　　要：外伤性增生性玻璃体视网膜病变（proliferative vitreoretinopathy,PVR）是视网膜脱离手术失败的主要原因,治疗棘手.玻璃体视网膜手术中内界膜的剥除、松解性视网膜切开术、玻璃体腔填充使用的全氟化碳液体、联合重轻型硅油填充等成为外伤性PVR手术治疗的新方向;药物治疗包括抗代谢药物、糖皮质激素、抑制纤维素生成药物等.新的药物治疗进展有基因治疗、免疫抑制剂、磷酸化糖蛋白等.可通过缓释微粒治疗等新疗法降低PVR发病率和严重程度.Traumatic proliferative vitreoretinopathy （PVR） is the main reason for the failure of retinal detachment surgery,which is very difficult to be cure.Internal hmiting membrane peeling,retinal release incision,vitreous cavity filling using perfluorocarbon liquid or using combined weight and light silicone oil are the new surgery treatment direction of PVR.Medications,such as antimetabolites,corticosteroids,drugs inhibiting cellulose,as well as the new therapy,such as gene therapy,immunosuppressants,phosphorylated glycoprotein etc.And the sustained-release fine particles therapy can reduce the morbidity and the severity of the PVR.

关 键 词：增生性玻璃体视网膜病变/外伤性 松解性视网膜切开术 骨桥蛋白 基质金属蛋白酶抑制剂 

分 类 号：R774.12[医药卫生—眼科]